---
title: "Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Economic impact on families"
description: "Formulary evidence on Envudeucitinib (ESK-001, FTP-637) in Moderate-to-severe plaque psoriasis: Economic impact on families. Topics: Extra housework, psychological pressure, and social disruption among 63 relatives and partners; Partner burden, including cleaning, by psoriasis severity: FamilyPso international study of 556 patients and partners; Burden on close relatives and partners by severity and patient quality of life: Psoriasis Registry Austria; Quality of life, anxiety, and depression in cohabitants of patients; 4 further topics. 8 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description/economic-impact-on-families"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Economic impact on families

<a id="heading-2.2.1.8.3"></a>

## 2.2.1.8.3 Economic Impact of Moderate-to-severe plaque psoriasis on Families

<a id="topic-2.2.1.8.3-1"></a>

### Extra housework, psychological pressure, and social disruption among 63 relatives and partners

> “Thirty-three subjects were interviewed and 30 replied by postal questionnaire. Twenty-eight of the 63 subjects were relatives (seven men and 21 women) and 35 were partners (16 men and 19 women).”
> “Seventy per cent stated that the treatment of their relative or partner resulted in them having to spend extra time on housework; 57% described psychological pressures including anxiety, being upset and being worried about the patient's future; 55% described social disruption due to lack of social confidence either because of embarrassment or because of the time required for care duties; 44% described limitations to holiday plans, sport and leisure activities and evenings out; 37% described limitations on their daily activities such as shopping, work and time spent with other family members; 37% felt that their close relationships had deteriorated. Only 8% described no effect at all on their QoL.”
> “The QoL of the relatives and partners (number of categories affected) was more closely related to the patients' QoL (DLQI: r = 0.77, P < 0.001; PDI: r = 0.67, P < 0.001) than to the objective disease severity scores (PASI: r = 0.34, P < 0.05).”

Source: [Eghlileb et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17459044/)

<a id="topic-2.2.1.8.3-2"></a>

### Partner burden, including cleaning, by psoriasis severity: FamilyPso international study of 556 patients and partners

> “A prospective cohort study was conducted in 11 centers in Austria, Canada, Germany, Italy, Spain, and Turkey.”
> “The cohort consisted of 556 people with psoriasis and their partners.”
> “Self-assessed high severity of psoriasis was a predictor for a higher burden in 4/5 FamilyPso domains.”
> “The highest scores were found for the acute/general emotional strain and the cleaning domains (Fig. 3). The partners’ burden increased by severity in each domain. The steepest slopes are found with emotional strain and cleaning.”
> “The data show that emotional aspects, such as a feeling of helplessness with the chronic illness of the partner, and increased cleaning efforts add to the burden that psoriasis imposes on partners.”

Source: [Mrowietz et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12436565/)

<a id="topic-2.2.1.8.3-3"></a>

### Burden on close relatives and partners by severity and patient quality of life: Psoriasis Registry Austria

> “250 plaque‐type psoriasis patients (58.4% males and 41.6% females) with mostly treatment‐controlled disease (mean PASI of 1.7 and Dermatology Life Quality Index (DLQI) of 4.1) were recruited from the Psoriasis Registry Austria (PsoRA) and their close relatives and partners were invited to participate in the study.”
> “Valid FamilyPso questionnaires were returned from 153 (61.2%) close relatives and partners. Correlation analysis revealed a significant association between PASI and DLQI (r = 0.512, p < 0.001), PASI and PFIS (r = 0.228, p = 0.006), and DLQI and PFIS (r = 0.210, p = 0.014).”
> “A small or larger disease burden was detected in nearly 78.7% of the male and 77.3% of the female relatives and partners quantified with categorized PFIS.”
> “The gender of the relatives and partners had no impact on the PFIS.”

Source: [Grossschaedl et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11150751/)

<a id="topic-2.2.1.8.3-4"></a>

### Quality of life, anxiety, and depression in cohabitants of patients

> “The study included patients, cohabitants, and controls, a total of 130 participants.”
> “The presence of psoriasis impaired the quality of life of 87.8% of the cohabitants. FDLQI scores of cohabitants were significantly associated with the DLQI scores of the patients (rs = 0.554; P < .001). Anxiety and depression levels did not differ between patients and cohabitants, but were significantly higher than in the controls (P < .001).”

Source: [Martínez-García et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24836080/)

<a id="topic-2.2.1.8.3-5"></a>

### Family Dermatology Life Quality Index: instrument for family members of patients with skin disease

> “A 10-item questionnaire, the Family Dermatology Life Quality Index (FDLQI), was finalized after modifications to the draft questionnaire based on feedback from families and dermatology professionals and on item reduction.”
> “A strong correlation was seen between the family members' FDLQI scores and patients' DLQI scores (r = 0.69), a significantly higher FDLQI score was seen for inflammatory skin diseases compared with noninflammatory diseases/isolated lesions (P < 0.0001), and there was a positive relationship between the family members' FDLQI scores and patients' disease severity (r = 0.49).”

Source: [Basra et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17300244/)

<a id="topic-2.2.1.8.3-6"></a>

### Lifestyle, emotional, and relationship consequences for family members: focus groups and interviews

> “We conducted focus groups and interviews with 23 individuals; 12 had a family member with AD, and 11 had a family member with psoriasis.”
> “Three major themes emerged: (1) lifestyle consequences-many daily activities for family members, including but not limited to leisure activities, sleep, and cleaning, were affected by AD or psoriasis; (2) emotional consequences-family members felt frustrated, worried, or embarrassed, among other concerns, because of their loved ones' AD or psoriasis; (3) relationships-relationships between family members and their loved ones with AD or psoriasis could become strained, and though family members might try to be sympathetic, doing so could be difficult because of their lack of understanding of how these diseases feel and personally affect their loved ones.”

Source: [Snyder et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/35618988/)

<a id="topic-2.2.1.8.3-7"></a>

### Family income by psoriasis severity: Polish specialty clinic

> “A total of 83 (45 male) psoriasis patients, treated at a Polish specialty clinic, were assessed for their financial and employment status.”
> “Patients' family income correlate negatively with psoriasis severity (Spearman's rho = -0.356; P < 0.01). Disease severity in patients with a family income below the social minimum was significantly higher (PASI: 20.5 ± 12.2) than in patients with a higher family income (PASI: 11.7 ± 7.7, P < 0.001).”
> “Family income was found to link disease severity to global QoL impairment (P < 0.05).”

Source: [Hawro et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/24852054/)

<a id="topic-2.2.1.8.3-8"></a>

### Caregivers of children with psoriasis: meta-analysis of 21 studies

> “Twenty‐one studies were included, encompassing 1038 children and 1161 caregivers.”
> “Across studies, 84.8% of children and 96.1% of caregivers experienced some degree of HrQOL impairment. Meta‐analysis revealed a moderate positive correlation between child disease severity (PASI scores) and caregiver HrQOL burden (r = 0.463), while no significant correlation was found with child age or disease duration.”

Source: [Perlmutter et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13423114/)

## Related pages
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Terms and abbreviations](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations.md)
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Product information and disease description](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Clinical evidence](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Economic information and modeling report](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: References](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references.md)
